Similar articles for PMID: 19254044

Year	Number of Results
1994	1
1996	1
2000	1
2001	2
2002	1
2003	1
2004	2
2005	3
2006	7
2007	2
2008	4
2009	5
2010	2
2011	2
2012	5
2013	10
2014	8
2015	6
2016	3
2017	11
2018	3
2019	2
2020	4
2021	7
2022	10
2023	6
2024	1

1

Neuropathic pain: quality-of-life impact, costs and cost effectiveness of therapy.

O'Connor AB. O'Connor AB. Pharmacoeconomics. 2009;27(2):95-112. doi: 10.2165/00019053-200927020-00002. Pharmacoeconomics. 2009. PMID: 19254044 Review.

2

Amitriptyline for neuropathic pain and fibromyalgia in adults.

Moore RA, Derry S, Aldington D, Cole P, Wiffen PJ. Moore RA, et al. Cochrane Database Syst Rev. 2012 Dec 12;12:CD008242. doi: 10.1002/14651858.CD008242.pub2. Cochrane Database Syst Rev. 2012. PMID: 23235657 Updated. Review.

3

A cost-utility comparison of four first-line medications in painful diabetic neuropathy.

O'Connor AB, Noyes K, Holloway RG. O'Connor AB, et al. Pharmacoeconomics. 2008;26(12):1045-64. doi: 10.2165/0019053-200826120-00007. Pharmacoeconomics. 2008. PMID: 19014205

4

Cost-Effectiveness of Treatment Options for Neuropathic Pain: a Systematic Review.

Ruiz-Negrón N, Menon J, King JB, Ma J, Bellows BK. Ruiz-Negrón N, et al. Pharmacoeconomics. 2019 May;37(5):669-688. doi: 10.1007/s40273-018-00761-6. Pharmacoeconomics. 2019. PMID: 30637713

5

The future of Cochrane Neonatal.

Soll RF, Ovelman C, McGuire W. Soll RF, et al. Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12. Early Hum Dev. 2020. PMID: 33036834

6

The humanistic and economic burden of systemic lupus erythematosus : a systematic review.

Meacock R, Dale N, Harrison MJ. Meacock R, et al. Pharmacoeconomics. 2013 Jan;31(1):49-61. doi: 10.1007/s40273-012-0007-4. Pharmacoeconomics. 2013. PMID: 23329592 Review.

7

A review of the health-related quality of life and economic impact of Parkinson's disease.

Dowding CH, Shenton CL, Salek SS. Dowding CH, et al. Drugs Aging. 2006;23(9):693-721. doi: 10.2165/00002512-200623090-00001. Drugs Aging. 2006. PMID: 17020395 Review.

8

Economic and health-related quality of life considerations of new therapies in Parkinson's disease.

Rubenstein LM, DeLeo A, Chrischilles EA. Rubenstein LM, et al. Pharmacoeconomics. 2001;19(7):729-52. doi: 10.2165/00019053-200119070-00003. Pharmacoeconomics. 2001. PMID: 11548910 Review.

9

Gabapentin versus tricyclic antidepressants for diabetic neuropathy and post-herpetic neuralgia: discrepancies between direct and indirect meta-analyses of randomized controlled trials.

Chou R, Carson S, Chan BK. Chou R, et al. J Gen Intern Med. 2009 Feb;24(2):178-88. doi: 10.1007/s11606-008-0877-5. Epub 2008 Dec 17. J Gen Intern Med. 2009. PMID: 19089502 Free PMC article.

10

Pharmacologic management part 1: better-studied neuropathic pain diseases.

Backonja MM, Serra J. Backonja MM, et al. Pain Med. 2004 Mar;5 Suppl 1:S28-47. doi: 10.1111/j.1526-4637.2004.04020.x. Pain Med. 2004. PMID: 14996228 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

100 results

Results by year